News articles about Aduro Biotech (NASDAQ:ADRO) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aduro Biotech earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 44.8823315139793 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Aduro BioTech, Inc. (ADRO) Stock Recap | Wallstreet Morning – Wall Street Morning (wallstreetmorning.com)
- Why Is Aduro Biotech (ADRO) Down 6.8% Since the Last Earnings Report? – Nasdaq (nasdaq.com)
- Aduro Biotech, Inc. (NASDAQ:ADRO) Trading Down – Insider Trading Activity (highlightpress.com)
- Technical Views: Tracking Shares of Aduro Biotech Inc (ADRO) – Financial News Review (finnewsreview.com)
Aduro Biotech (ADRO) opened at 11.15 on Tuesday. The company’s market capitalization is $831.92 million. The stock has a 50 day moving average of $11.98 and a 200 day moving average of $10.98. Aduro Biotech has a 12 month low of $8.75 and a 12 month high of $15.52.
Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.02. The company had revenue of $5.90 million during the quarter, compared to analysts’ expectations of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. Aduro Biotech’s quarterly revenue was down 84.9% compared to the same quarter last year. During the same period last year, the firm posted $0.03 earnings per share. Equities analysts anticipate that Aduro Biotech will post ($1.37) EPS for the current fiscal year.
ADRO has been the topic of several analyst reports. HC Wainwright set a $18.00 price target on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research lowered shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. BidaskClub lowered shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Canaccord Genuity set a $30.00 price target on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, Cowen and Company initiated coverage on shares of Aduro Biotech in a research report on Tuesday, July 18th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. Aduro Biotech presently has a consensus rating of “Buy” and a consensus target price of $19.00.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.themarketsdaily.com/2017/09/12/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-aduro-biotech-adro-stock-price.html.
In related news, insider Thomas W. Dubensky sold 50,000 shares of the business’s stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $11.33, for a total value of $566,500.00. Following the transaction, the insider now directly owns 51,700 shares of the company’s stock, valued at approximately $585,761. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Stephen T. Isaacs sold 40,000 shares of the business’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $10.50, for a total transaction of $420,000.00. Following the completion of the transaction, the insider now directly owns 125,486 shares in the company, valued at $1,317,603. The disclosure for this sale can be found here. Insiders sold a total of 453,923 shares of company stock worth $5,212,846 over the last three months. 6.60% of the stock is owned by insiders.
Aduro Biotech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.